Remove 2018 Remove Community Remove Medical Remove Provider
article thumbnail

Dashboard of Advancement and Success for Health Services Research (DASH) 2.0 [Research capacity building]

Annals of Family Medicine

Context: The Lehigh Valley Practice and Community Based Research Network(LV-PCBRN) conducts weekly meetings to engage members in discussion about active and future research, and quality improvement projects conducted by colleagues, residents, and medical students.

article thumbnail

How Mental Health & SUD Bias Impact ED Physical Care

Physician's Weekly

“Patients with mental health and/or SUDs disproportionately seek medical care in EDs, yet research rarely examines first-hand accounts of their experiences,” wrote study corresponding author Linda M. Embedding a psychiatric registered nurse or SUD counselor can decompress boarding and free physicians to manage medical presentations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Green Practice News: April 2025

My Green Doctor

New Research: Teaching Patients about Climate Resilience Newly published original research co-authored by My Green Doctor’s Dr. Todd Sack concludes that, “ the medical office waiting room appears to be an accepted, time-efficient, and effective site to communicate knowledge on climate change and health. ” Contact us today!

article thumbnail

Episode 262: Anti-Racism in Medicine Series – Episode 18 – Remedying Health Inequities Driven by the Carceral System

The Clinical Problem Solvers

The ways to remedy the negative impacts of incarceration are to incarcerate fewer people and to invest in communities. Providing communities with the resources they need to survive, such as educational opportunities, jobs, and quality healthcare, will eliminate the need for incarceration.

article thumbnail

At Long Last, FDA Unveils Plan for Rare Disease Innovation Hub

FDA Law Blog

Importantly, the Hub is intended to establish a new model within FDA, which leverages cross-Agency expertise in providing guidance and conducting reviews for products for rare disease populations. those reviewed by the CDER Division of Rare Diseases and Medical Genetics).

article thumbnail

Biden Administration Facing Renewed Pressure to Legalize Cannabis

FDA Law Blog

As a reminder, cannabis remains a schedule I substance under the federal Controlled Substances Act (“CSA”), which by definition means it does not have an accepted medical use in treatment in the United States and thus cannot be legally sold or marketed for any purpose. Cole providing guidance to U.S. 21 U.S.C. § 812(b)(1).

Medical 96
article thumbnail

Approaches for Quelling Stigma related to COVID-19

BMJ

A multilayered view of stigmatizing discourses lays the foundation for eliciting a series of suggestions for quelling stigma, to be implemented at the individual, community, and national levels, as suggested by the WHO. Yet, as Tenkorang 7 made the point, it is simply not enough to only implement approaches at the community level.